N
Nautilus Biotechnology NAUT
$2.32
−2.52%
Nov 13
1W
1M
3M
6M
1Y
3Y
5Y
Activities
Earnings release
The day the company publishes its quarterly accounts: revenue, profit, and often its outlook. The price sometimes moves sharply that day, in either direction. Over the long term, what matters is the trend of profits from one quarter to the next, not the reaction of the day.
Posts
No posts about NAUT yet.
About Nautilus Biotechnology, Inc. Common Stock
Nautilus Biotechnology is a Seattle-based development-stage company building a platform to measure proteins and their variants (the proteome) in single molecules. It has no commercial product yet and earns only small grant and early-access service revenue. It funds its research from cash raised from investors.